

AMENDMENT

Prior to consideration of the following Remarks, Applicants request that the following Amendments be entered:

In the Claims:

- (a.) In claim 5, before the word "calpain" insert the word – micro- --.
- (b.) In claim 7, before the word "calpain" insert the word – micro- --.
- (b.) Please cancel claim 17.
- (c.) Please add the following new claims 21-36:
 - 21. (new) The method of claim 6 wherein said adenoviral vector is replication deficient.
 - 22. (new) The method of claim 21 wherein said replication deficient adenoviral vector encodes a therapeutic transgene.
 - 23. (new) The method of claim 22 where said transgene is selected from the group consisting of cytostatic genes and pro-apoptotic genes.
 - 24. (new) The method of claim 23 wherein the gene is a cytostatic gene.
 - 25. (new) The method of claim 24 wherein the gene is the p21 gene.
 - 26. (new) The method of claim 23 wherein the gene is a pro-apoptotic gene.
 - 27. (new) The method of claim 26 wherein the gene is p53.
 - 28. (new) The method of claim 5 wherein the vector is replication competent.
 - 29. (new) The method of claim 28 wherein the replication competent vector is a conditionally replicating viral vector.
 - 30. (new) The method of claim 29 wherein the conditionally replicating viral vector further comprises an expression cassette which expresses a pro-apoptotic gene.
 - 31. (new) The method of claim 30 wherein the pro-apoptotic gene is the E3-11.6K gene.
 - 32. (new) The method of claim 5 wherein the method is practiced *in vitro*.